Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP patientsChinese?
Not Applicable
Terminated
- Conditions
- Non-Cardiac Chest Pain
- Registration Number
- NCT00164801
- Lead Sponsor
- Chinese University of Hong Kong
- Brief Summary
The effect of baclofen (GABAB agonist), diltiazem (muscle relaxant) and placebo will be compared in a double-blinded randomized study for the treatment of NCCP. Cerebral cortical, brainstem and spinal evoked potentials before and after treatment will be evaluated. Results of this study will shed lights on pathogenesis and treatment of NCCP in Chinese.We hypothesize that Baclofen alleviates visceral hyperalgesia in NCCP patients by suppressing afferent sensory pathway.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Consecutive patients with monthly angina-like chest pain and negative coronary angiogram or scintigraphy
- Age between 18-70
- Gastroesophageal reflux disease
- Psychiatric illness
- Cerebrovascular accident
- Active peptic ulceration
- Heart failure or cardiac bradyarrhythmia
- Epilepsy
- Pregnancy or lactating female
- Previous hypersensitivity to muscle relaxant
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Esophageal sensory and pain thresholds
- Secondary Outcome Measures
Name Time Method Symptom severity of chest pain at the end of treatment Evoked potential responses
Trial Locations
- Locations (1)
Endoscopy Centre, Prince of Wales Hospital
🇨🇳Hong Kong, China